Table 3. Cox hazard regression analysis of progression-free survival.
| Progression-free survival | |||
|---|---|---|---|
| Variable | HR | 95% CI | p |
| Gender | 1.143 | 0.609-2.143 | 0.677 |
| Age | 0.537 | 0.312-0.925 | 0.025 |
| Preoperative ECOG performance status | 1.095 | 0.637-1.883 | 0.743 |
| Preoperative Karnofsky index | 0.996 | 0.963-1.030 | 0.824 |
| Type of surgery (resection) | 1.190 | 0.707-2.003 | 0.512 |
| Tumor location | 1.048 | 0.670-1.638 | 0.838 |
| Postoperative Karnofsky index | 0.963 | 0.930-0.998 | 0.037 |
| Postoperative radiotherapy | 0.187 | 0.065-0.541 | 0.002 |
| Postoperative chemotherapy | 0.411 | 0.199-0.849 | 0.016 |
| Temozolomide | 0.644 | 0.329-1.260 | 0.198 |
| Alkylating nitrosourea compounds (CCNU, BCNU) | 1.089 | 0.422-2.813 | 0.860 |
| PCV | 0.312 | 0.095-1.022 | 0.054 |
| Interval between surgery and postoperative treatment | 0.493 | 0.236-1.000 | 0.049 |
Bold = statistical significance; 95% CI = 95% confidence interval; HR = hazard ratio; p = p value; ECOG = Eastern Cooperative Oncology Group score; CCNU = lomustine; BCNU = carmustine; PCV = procarbazine, lomustine, vincristine